The removal of SEC investigation risk and class action dismissal, combined with a strengthened balance sheet from the Zydus deal and the start of Phase 3 enrollment, represent a material de-risking of the BOT+BAL program. Monitor for regulatory submission updates in the U.S. and EU, and for the next quarterly cash burn rate to gauge whether the $50M annualized operating expense target is being met.
AGEN drugs
AGEN drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 11 $3.26entry
- T+1 · 6mo ago +5.52%α +5.66% · $3.44
- T+5 · 6mo ago −3.07%α −2.98% · $3.16
- T+20 · 5mo ago −4.60%α −4.30% · $3.11
- T+60 · 3mo ago +138.65%α +134.26% · $7.78
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Agenus reported Q1 2026 total revenue of $33.7M (up from $24.1M YoY) and net income of $39.2M vs a net loss of $26.4M in Q1 2025, driven by $29.1M in non-cash royalty revenue and $4.6M in pre-commercial product revenue from BOT+BAL early access programs. The company ended the quarter with $35.0M in cash (up from $3.0M at year-end 2025) after closing the Zydus collaboration, which delivered $91M in upfront capital. The SEC investigation concluded with no enforcement action, and the related securities class action was dismissed, removing two key legal overhangs.
Key Financial Metrics
Key Facts
- Total revenue $33.7M in Q1 2026 vs $24.1M in Q1 2025 (up 39.8% YoY)
- Net income of $39.2M vs net loss of $26.4M in Q1 2025
- Operating income of $15.1M vs operating loss of $(13.3)M in Q1 2025
- Cash and equivalents $35.0M at March 31, 2026 vs $3.0M at December 31, 2025
- Zydus collaboration closed in January 2026 with $91M upfront capital
- SEC investigation concluded May 4, 2026 with no enforcement action recommended
- Securities class action dismissed in its entirety by U.S. District Court on March 24, 2026
- Phase 3 BATTMAN trial commenced patient enrollment in April 2026
- Pre-commercial product revenue of $4.6M from BOT+BAL early access programs
- Subsequent to quarter-end, received $11.7M in net proceeds from ATM equity sales
Financial Impact
Revenue increased 39.8% YoY to $33.7M; net income swung positive by $65.6M vs prior year loss; cash position improved by $32.0M from year-end 2025
Risk Factors
- Lead plaintiff has filed a Notice of Appeal on the class action dismissal
- Cash payments of $51.8M in Q1 included one-time Zydus closing costs; recurring burn rate still to be confirmed
- BOT+BAL remains unapproved; regulatory outcomes are binary and years away
- Dilution risk from ATM program, $11.7M in net proceeds raised post-quarter-end
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-215838 |
| Document: agen-20260511.htm | 0001193125-26-215838 |
| Document: 0001193125-26-215838-index-headers.html | 0001193125-26-215838 |
| Document: 0001193125-26-215838-index.html | 0001193125-26-215838 |
| Document: 0001193125-26-215838.txt | 0001193125-26-215838 |
| 8-K Data (Synthetic) | 0001193125-26-215838 |
Track record
12 reports on AGEN
2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +25.70% at T+60 after the Dec 4, 2025 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $6.97 Now $6.29 −9.76% settles Feb 12
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.44 Now $6.29 −2.33% settles Feb 3
- Aug 12, 202613w ago 8-K Neutral 2/10 Entry $7.00 to $6.90 Now $6.29 −10.14% ▼ −1.43% +3.81% vs SPY
- Aug 12, 202613w ago Institutional Cluster Mixed 4/10 Entry $6.90 to $6.97 Now $6.29 −8.84% ▲ +1.01% +5.89% vs SPY
- Aug 7, 202614w ago S-3 Bearish 7/10 Entry $7.00 to $6.76 Now $6.29 +10.14% ▲ +3.43% +1.53% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.49 to $6.84 Now $6.29 −16.02% ▼ −8.68% −7.01% vs SPY
- Jul 17, 202617w ago S-3 Bearish 5/10 Entry $4.97 to $6.95 Now $6.29 −26.56% ▼ −39.84% −35.00% vs SPY
- Jul 13, 202618w ago 8-K Bearish 6/10 Entry $6.12 to $7.49 Now $6.29 −2.78% ▼ −22.39% −18.39% vs SPY
- May 13, 202626w ago DEFA14A Neutral 4/10 Entry $3.47 to $6.96 Now $6.29 +81.27% ▲ +100.58% +96.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers